沙利度胺治疗白塞病的临床研究  

Clinical study on the treatment of thalidomide on patients with Behcet's

作　　者：戴禄寿[1] 谢军培[1] 戴益琛[1] 宋维芳[1] 李东福[1] 

机构地区：[1]解放军第174医院,福建厦门361003

出　　处：《临床军医杂志》2011年第1期21-22,共2页Clinical Journal of Medical Officers

摘　　要：目的研究沙利度胺在白塞病治疗中的作用。方法对符合白塞病诊断标准及完成治疗的21例我院门诊患者,采用自身治疗前后对照,给沙利度胺100 mg 2次/d,持续服用4周,第5～12周给沙利度胺100 mg 1次/d;第13～24周给沙利度胺50 mg 1次/d,疗程为6个月。疗程结束后复查CD3及CD4,CD8,CD4/CD8,及内镜评价疗效。结果总有效率85.7%,治疗前后CD3、CD4、CD8、CD4/CD8比较有明显差异,(P<0.05)。6个月内复发2例(9.5%),12个月内复发4例(19.1%)。结论沙利度胺能有效治疗白塞病,无明显副作用。Objective To investigate the clinical efficacy of thalidomide on patients with Behcet＇s.Methods 21 out-patients were treated by thalidomide 100mg twice daily for 4 weeks and thalidomide 100 mg once daily in 5 weeks to 12 weeks.The thalidomide 50mg once daily in 13 weeks to 24 weeks.After the treatment course of six months,CD3,CD4,CD8,CD4/CD8 were examined and treatment was evaluated by Endoscopy.Results The total effective rate was 85.7%.However,CD3,CD4,CD8 and CD4/CD8 had significant difference before and after treatment（P〈0.05）.Conclusion Thalidomide has good treatment effect on patients with Behcet＇s and there was no obvious adverse reaction of treatment.

关 键 词：沙利度胺 白塞病 

分 类 号：R543[医药卫生—心血管疾病]